stoxline Quote Chart Rank Option Currency Glossary
  
Kymera Therapeutics, Inc. (KYMR)
33.76  -0.17 (-0.5%)    04-17 16:00
Open: 34.39
High: 34.41
Volume: 433,665
  
Pre. Close: 33.93
Low: 33.17
Market Cap: 2,063(M)
Technical analysis
2024-04-17 4:47:54 PM
Short term     
Mid term     
Targets 6-month :  45.91 1-year :  50.34
Resists First :  39.3 Second :  43.09
Pivot price 36.75
Supports First :  33.16 Second :  27.59
MAs MA(5) :  34.97 MA(20) :  37.61
MA(100) :  32.56 MA(250) :  25.75
MACD MACD :  -1.4 Signal :  -0.9
%K %D K(14,3) :  5 D(3) :  8.9
RSI RSI(14): 34.4
52-week High :  45.31 Low :  9.6
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ KYMR ] has closed above bottom band by 12.2%. Bollinger Bands are 13.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 34.46 - 34.7 34.7 - 34.89
Low: 32.55 - 32.87 32.87 - 33.12
Close: 33.31 - 33.75 33.75 - 34.09
Company Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Headline News

Wed, 17 Apr 2024
Kymera Therapeutics Enters Oversold Territory (KYMR) - Nasdaq

Wed, 03 Apr 2024
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656 ... - Quantisnow

Thu, 21 Mar 2024
Is Kymera Therapeutics Inc (KYMR) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Thu, 21 Mar 2024
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - Seeking Alpha

Fri, 08 Mar 2024
Do Analysts Agree Friday on Kymera Therapeutics Inc (KYMR) Stock's Target Price? - InvestorsObserver

Tue, 27 Feb 2024
Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know - Markets Insider

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 61 (M)
Shares Float 40 (M)
Held by Insiders 1.3 (%)
Held by Institutions 102.7 (%)
Shares Short 9,060 (K)
Shares Short P.Month 8,250 (K)
Stock Financials
EPS -2.52
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.11
Profit Margin -187 %
Operating Margin -40.4 %
Return on Assets (ttm) -17.6 %
Return on Equity (ttm) -33.3 %
Qtrly Rev. Growth 196.6 %
Gross Profit (p.s.) 0
Sales Per Share 1.28
EBITDA (p.s.) -2.68
Qtrly Earnings Growth 0 %
Operating Cash Flow -103 (M)
Levered Free Cash Flow -98 (M)
Stock Valuations
PE Ratio -13.4
PEG Ratio -6.4
Price to Book value 4.74
Price to Sales 26.25
Price to Cash Flow -20.07
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android